A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs GSK 2330811 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Proof of concept
- Sponsors GlaxoSmithKline
- 12 Jan 2018 Planned End Date changed from 18 Feb 2019 to 15 Jul 2019.
- 12 Jan 2018 Planned primary completion date changed from 18 Feb 2019 to 15 Jul 2019.
- 27 Nov 2017 Planned End Date changed from 31 Dec 2018 to 18 Feb 2019.